论文部分内容阅读
《Wall Street J》1984年11月13日。美国迈阿密海滩消息:基因技术公司研究人员在此地举行的美国心脏病学会会议中说,基因工程制造的组织纤维蛋白溶酶原激活剂(TPA)已首次试用于49名心脏病猝发的病人,其中35例的溶血栓作用于30—45分钟内奏效。用药方式是由静脉输注。基因技术公司临床研究部主任Elliott Grossbard说,一旦血栓消失,冠状动脉血流恢复正常。病人分别在马州综合医院、约翰斯·霍布金斯医学研究院及华盛顿大学附属医院试用。
Wall Street J, November 13, 1984. MIAMI BEACH, USA (Reuters Health) - Gene Technology Inc. researchers here at the American College of Cardiology meeting said that tissue engineered tissue plasminogen activator (TPA) has been tested for the first time in 49 patients with heart-burst, of which 35 cases of thrombolytic effect within 30-45 minutes worked. Medication is by intravenous infusion. Elliott Grossbard, director of clinical research at Gene Technologies, said coronary blood flow returned to normal once the thrombus disappeared. Patients were tested at the Mazhou General Hospital, the Johns Hopkins Medical Institute and the Washington University Hospital.